Ken Griffin Insmed Inc Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$62.0 - $79.01 $2.26 Million - $2.88 Million	-36,500 Reduced 11.56%	279,300 $20.4 Million
Q2 2024 Aug 14, 2024	BUY	$22.0 - $69.71 $4.13 Million - $13.1 Million	187,500 Added 146.14%	315,800 $21.2 Million
Q1 2024 May 15, 2024	BUY	$25.72 - $29.94 $2.98 Million - $3.47 Million	115,800 Added 926.4%	128,300 $3.48 Million
Q4 2023 Feb 14, 2024	SELL	$23.42 - $31.74 $1.82 Million - $2.46 Million	-77,600 Reduced 86.13%	12,500 $387,000
Q3 2023 Nov 14, 2023	BUY	$19.86 - $26.93 $1.36 Million - $1.85 Million	68,600 Added 319.07%	90,100 $2.28 Million
Q2 2023 Aug 14, 2023	BUY	$16.44 - $21.1 $184,128 - $236,320	11,200 Added 108.74%	21,500 $453,000
Q1 2023 May 15, 2023	SELL	$16.26 - $21.73 $91,056 - $121,688	-5,600 Reduced 35.22%	10,300 $175,000
Q4 2022 Feb 14, 2023	BUY	$16.98 - $23.15 $33,960 - $46,300	2,000 Added 14.39%	15,900 $317,000
Q3 2022 Nov 14, 2022	BUY	$20.88 - $28.21 $290,232 - $392,119	13,900 New	13,900 $299,000

465

182M

2.27M

3.33M

Ticker INSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,476,992
Market Cap $8.98B
Description
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.